Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Rhea-AI Summary

Advanced Biomed (Nasdaq: ADVB) launched a 120-case, IRB-approved feasibility study with Chi‑Mei Medical Center to evaluate the A+PerfusC perfusion 3D cell culture platform using circulating tumor cells from liquid biopsy. Case collection began February 2026; interim comparative data are expected May–June 2026 and full completion is targeted by year-end 2026. The study compares ex-vivo drug sensitivity results to actual patient outcomes and follows the platform’s September 2025 commercial launch. Under the collaboration, both parties will share project-related intellectual property and research outcomes.

Positive

• 120-case feasibility study initiated with IRB approval
• Interim comparative data targeted May–June 2026
• Full study completion targeted by year-end 2026
• Platform commercially launched in September 2025

Negative

• Feasibility, non-interventional design; not definitive clinical validation
• Platform use as a predictive Clinical Decision Support tool is contingent on favorable results and regulatory review

News Market Reaction

+1.09%

2 alerts

+1.09% News Effect

+3.2% Peak Tracked

+$71K Valuation Impact

$7M Market Cap

0.1x Rel. Volume

On the day this news was published, ADVB gained 1.09%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $71K to the company's valuation, bringing the market cap to $7M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Feasibility study size: 120 cases Equity line capacity: $25,000,000 Commitment fee shares: 1,650,710 shares +5 more

8 metrics

Feasibility study size 120 cases Non-interventional feasibility study for A+PerfusC™ at Chi‑Mei Medical Center

Equity line capacity $25,000,000 Maximum common stock sales under equity line with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD.

Commitment fee shares 1,650,710 shares Shares issued as $500,000 commitment fee under equity line agreement

Private placement shares 4,000,000 shares Shares sold at $0.062 per share for total proceeds of $248,000

Private placement price $0.062 per share Pricing for 4,000,000-share private placement on January 28–29, 2026

Quarterly net loss $386,901 Net loss for three months ended September 30, 2025

Cash balance $2,656,519 Cash as of September 30, 2025

Reverse split range 1-for-2 to 1-for-100 Approved reverse stock split ratio range to support Nasdaq listing

Market Reality Check

Price: $0.2401 Vol: Volume 10,699 is below th...

low vol

$0.2401 Last Close

Volume Volume 10,699 is below the 20-day average of 39,106 (relative volume 0.27x). low

Technical Price $0.2375 is trading below the 200-day MA of $0.58 and 94.21% below the 52-week high.

Peers on Argus

ADVB was down 3.85% with low volume, while only one momentum peer (XWEL) also sh...

1 Down

ADVB was down 3.85% with low volume, while only one momentum peer (XWEL) also showed a down move. Other sector peers showed mixed moves between gains and losses, indicating ADVB’s action appeared more stock-specific than sector-driven.

Historical Context

2 past events · Latest: Dec 30 (Neutral)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Dec 30	Subsidiary divestiture	Neutral	+1.5%	Sold Hong Kong subsidiary and centralized clinical trials in Taiwan.
Sep 19	Product launch	Positive	-17.2%	Launched A+PerfusC 3D cell culture platform targeting precision medicine and drug discovery.

Pattern Detected

Recent product-launch news saw a negative reaction, while a corporate divestiture saw a modest gain, indicating mixed alignment between news tone and price moves.

Recent Company History

Recent history shows ADVB balancing strategic restructuring and platform development. On Sep 19, 2025, it launched the A+PerfusC™ 3D cell culture platform, but shares fell 17.18% despite the positive commercialization milestone. On Dec 30, 2025, it sold its Hong Kong subsidiary for US$23,000, centralizing trials in Taiwan, and the stock rose 1.5%. Today’s feasibility-study collaboration builds directly on the prior A+PerfusC™ launch by seeking clinical validation data.

Market Pulse Summary

This announcement advances A+PerfusC™ from commercial launch toward clinical validation through a 12...

Analysis

This announcement advances A+PerfusC™ from commercial launch toward clinical validation through a 120‑case feasibility study linking ex‑vivo drug sensitivity to patient outcomes. It complements prior news on the platform’s capabilities and the company’s broader precision oncology strategy. Filings highlight ongoing net losses, small-scale equity raises, and reverse split authorization, so investors may watch for study readouts, further validation studies, capital needs, and Nasdaq listing developments as key future checkpoints.

Key Terms

liquid biopsy, circulating tumor cells, 3d cell culture, xenograft, +3 more

7 terms

liquid biopsy medical

"circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

circulating tumor cells medical

"A+PerfusC platform from circulating tumor cells obtained via liquid biopsy"

Circulating tumor cells are cancer cells that break away from a tumor and travel in the bloodstream, detectable through a blood test. Investors care because their presence and number can act like a real-time signal — similar to footprints showing where a person has been — revealing disease progression, response to treatment, or risk of metastasis, which influences the market value of diagnostics, therapies and clinical trial outcomes.

3d cell culture medical

"A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator"

A laboratory method for growing living cells in three-dimensional structures that more closely mimic real tissues than flat, two-dimensional dishes. Because these 3D models behave more like actual organs—think of a miniature building instead of a single floor—they can give more reliable results for testing drugs, safety and disease models, which can reduce development time, lower late-stage failures and affect the value of companies working in biotech, pharmaceuticals and lab tools.

xenograft medical

"Two‑dimensional cell culture models and xenograft animal models frequently fail"

A xenograft is biological tissue or cells taken from one species and placed into another, most commonly human tumor cells implanted into laboratory animals to study disease or test drugs. Investors watch xenograft results because they serve like a controlled dress rehearsal for a therapy: positive responses in these models can de‑risk programs, attract funding or partnerships, and influence the likelihood and timing of clinical trials and regulatory milestones.

microfluidic technical

"isolates high‑viability circulating tumor cells using label‑free microfluidic technology"

Microfluidic describes technology that controls and moves extremely small amounts of liquids through tiny channels on a chip, like a miniature plumbing system for droplets. It matters to investors because it can cut the time, cost and materials needed for medical tests, drug discovery and small-scale manufacturing, potentially creating faster product development, lower production costs and new revenue opportunities for companies using the technology.

clinical decision support regulatory

"support its use as a predictive tool for treatment response and Clinical Decision Support (CDS)"

Software tools and information services that give clinicians patient-specific recommendations, alerts, or diagnostic and treatment options at the point of care—like a GPS that suggests routes based on current traffic, but for medical decisions. Investors care because these tools can improve patient outcomes, reduce errors and costs, drive demand for healthcare IT, and face regulatory and reimbursement rules that affect commercial adoption and revenue potential.

institutional review board regulatory

"The feasibility study is a non‑interventional clinical research project that received Institutional Review Board approval."

An institutional review board is an independent committee that reviews and approves research involving people to make sure studies are safe, ethical, and protect participants’ rights and privacy. For investors, IRB approval is a gatekeeper: it can determine whether a clinical trial can start or continue, affecting timelines, regulatory risk, cost and the credibility of trial results—similar to a safety inspector whose sign-off is required before work can proceed.

AI-generated analysis. Not financial advice.

Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company’s A+PerfusC^™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro.

The feasibility study is a non‑interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi‑Mei Medical Center, with interim comparative data expected in May–June 2026 and full study completion targeted by year‑end 2026. The study will compare ex‑vivo drug sensitivity results generated by the A+PerfusC platform from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance. It follows the Company’s September 2025 commercial launch of the A+PerfusC integrated perfusion 3D cell culture platform and represents an additional avenue to convert the system’s laboratory strengths into evidence that can be used in clinical practice.

This collaboration is significant because it seeks to address a central limitation of current preclinical and guideline‑driven approaches to oncology treatment selection. Two‑dimensional cell culture models and xenograft animal models frequently fail to recapitulate the complex, patient‑specific biology of human tumors and are constrained by low throughput and long turnaround times. By contrast, the A+PerfusC platform isolates high‑viability circulating tumor cells using label‑free microfluidic technology and grows them in automated 3D culture arrays that enable parallel testing of multiple drugs and combinations. This functional, patient-derived testing approach aims to shorten the time to an evidence‑based treatment decision, reduce exposure to ineffective therapies and their toxicities, and provide clinicians with a practical tool to prioritize therapies most likely to benefit an individual patient.

Beyond direct patient impact, the platform also addresses practical and ethical constraints associated with animal‑based models. Replacing large cohorts of mice with high‑density arrays of patient‑derived tumor spheroids enables high‑throughput screening that is not feasible with xenografts, while Advanced Biomed’s automated A+PerfusC^TM system is intended to reduce labor intensity and scale functional testing to clinically actionable timeframes. The Company expects the feasibility study’s results to inform the design of subsequent, larger clinical validation studies and to support its use as a predictive tool for treatment response and Clinical Decision Support (CDS), pending favorable outcomes and regulatory review.

“We believe the A+PerfusC platform can materially improve how oncologists select therapies by delivering patient‑specific, functional drug sensitivity data derived from a minimally invasive liquid biopsy,” said Dr. Yi Lu, Chief Executive Officer of Advanced Biomed. “This feasibility study with Chi‑Mei Medical Center is a critical step toward demonstrating the platform’s real‑world predictive value and advancing precision oncology beyond genomic inference to functional, individualized testing.”

Advanced Biomed and Chi‑Mei Medical Center will jointly conduct the non‑commercial clinical research and collaborate on subsequent commercial development. Under the Agreement, both parties will share rights to project-related intellectual property and research outcomes.

About Advanced Biomed Inc. 
Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.

Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.

For more information, please visit: www.advanbiomed.com.

Forward‑Looking Statements 
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com

FAQ

What is the scope of Advanced Biomed's 120-case study (ADVB) with Chi‑Mei Medical Center?

The study is a 120-case, IRB-approved feasibility project comparing ex-vivo drug sensitivity to patient outcomes. According to the company, it uses circulating tumor cells from liquid biopsy to test the A+PerfusC platform and began case collection in February 2026.

When will Advanced Biomed (ADVB) release interim results from the A+PerfusC feasibility study?

Interim comparative data are expected in May–June 2026. According to the company, those interim readouts will compare platform drug-sensitivity results with actual clinical outcomes to assess predictive correlation.

How does the A+PerfusC platform test drug sensitivity in the ADVB study?

A+PerfusC isolates high-viability circulating tumor cells and grows automated 3D culture arrays for parallel drug testing. According to the company, it uses label-free microfluidic capture and perfusion-based culture to mimic physiological conditions.

What are the study's endpoints and completion timeline for Advanced Biomed (ADVB)?

The study compares ex-vivo drug sensitivity results with patient clinical outcomes; full completion is targeted by year-end 2026. According to the company, results will inform larger validation studies and potential clinical use.

Does the Chi‑Mei collaboration affect Advanced Biomed's intellectual property rights for A+PerfusC (ADVB)?

Under the Agreement, both parties will share rights to project-related intellectual property and research outcomes. According to the company, IP and outcomes from the project will be jointly held by Advanced Biomed and Chi‑Mei Medical Center.

Will the A+PerfusC feasibility study immediately change clinical practice for oncology patients (ADVB)?

No; the feasibility study is intended to generate evidence but is not immediate clinical validation. According to the company, broader clinical adoption depends on favorable outcomes, subsequent validation studies, and regulatory review.